PT -期刊文章盟Loredana Storelli AU -玛丽亚·a·罗卡AU -穆罕默德Aboulwafa盟Paola Valsasina AU -保罗Preziosa盟-诺阿Copetti AU -亚历克斯·罗维拉盟- Xavier好吃盟休·卡尼AU -奥尔加Ciccarelli AU -露西马修斯盟杰奎琳宫非盟-安东尼奥Gallo盟Alvino Bisecco Carsten卢卡斯盟盟- -芭芭拉Bellenberg AU -吉安卡洛Comi AU -马西莫菲利皮主持TI - 3 d的结合使用T1和t2加权序列改善颈绳病变检测多发性硬化症患者:一项多中心研究3 t (P4.362) DP - 2017年4月18日TA -神经病学PG - P4.362 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P4.362.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/P4.362.full所以Neurology2017 4月18日;首页88 AB -目的:评估病变3日可视化dt1-weighted magnetization-prepared快速gradient-echo (MPRAGE)和t2加权或short-tau反转恢复(搅拌)扫描获得的3.0 t先生在一个大型数据集的多发性硬化(MS)患者在6个欧洲网站学习。背景:脊髓女士是一个雄辩的网站,经常参与颈脊髓损伤可以找到在病程早期,他们有助于诊断过程。在临床实践中,脊髓病变发现质子密度或t2加权矢状扫描。使用t1高分辨率序列可能提高脊髓损伤检测。设计/方法:两个评级机构盲目评价脊髓损伤数,水平从203 MS患者和横向位置。损伤评估使用T2 /搅拌,T1-MPRAGE,然后T2 /搅拌和T1-MPRAGE在一起。最后达成共识病变数量和位置。病灶计数比较使用混合效应模型调整的网站。Inter-observer和inter-sequence损伤评估数量和位置使用协议一致性相关系数(CCC)和科恩kappa指数。结果:病变检测T2 /搅拌是685年和717年(CCC = 0.88),当他们698年和708年(CCC = 0.92) T1-MPRAGE评定等级的# 1和# 2,分别。病变数量显著增加在使用两个序列在一起(术中,0.001; lesion number=763 and 746, respectively; CCC=0.91). Cervical cord lesions were most frequently located at the level of C2 (31%), C3 (15.7%) and C4 (18.1%), with a high agreement between T2/STIR and T1-MPRAGE scans (Cohen’s kappa=0.985). T1-MPRAGE scans allowed reliable lesion localization on the transverse plane, with 59% involvement of the lateral cord columns, 31% of the posterior cord, and 10% of the anterior cord.Conclusions: The combined use of sagittal T1-MPRAGE and T2/STIR improves MS cord lesion detection and localization. This might help diagnosis and ameliorate correlations with disability.Study Supported by:This study has been partially supported by a grant from Fondazione Italiana Sclerosi Multipla (FISM 2014/PMS/6). Mohammad Aboulwafa was supported by the ECTRIMS-MAGNIMS Fellowship in Magnetic Resonance Imaging.Disclosure: Dr. Storelli has nothing to disclose. Dr. Rocca has received personal compensation for activities with Novartis, Biogen Idec, Teva Neurosciences and Genzyme as a speaker. Dr. Aboulwafa has nothing to disclose. Dr. Valsasina has nothing to disclose. Dr. Preziosa has received personal compensation for activities with Biogen Idec, Novartis and ExceMED as a speaker. Dr. Copetti has nothing to disclose. Dr. Rovira has received personal compensation for activities with Genzyme, Novartis, Biogen, Bracco, and Teva. Dr. Montalban has received personal compensation for activities with Almirall, Bayer, Biogen, Celgene, Sanofi Genzyme, Merck, Novartis, Roche, and Teva Pharmaceutical. Dr. Kearney has nothing to disclose. Dr. Ciccarelli has received personal compensation for activities with Novartis, Biogen and GE as a consultant. Dr. Matthews has nothing to disclose. Dr. Palace has received personal compensation for activities with Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma, Alexion and Bayer Schering as an advisor. Dr. Gallo has received personal compensation for activities with Biogen, Sanofi-Aventis, Merck Serono, Genzyme, Teva, Bayer-Schering and Novartis as a speaker along with travel grants. Dr. Bisecco has nothing to disclose. Dr. Lukas has nothing to disclose. Dr. Bellenberg has nothing to disclose. Prof. Comi has received personal compensation for activities with Novartis, Teva Pharmaceutical Ind. Ltd, Sanofi, Genzyme, Merck Serono, Bayer, Actelion Sano as a speaker, consultant or participating on an advisory board. Dr. Filippi has received personal compensation for activities with Biogen Idec, Excemed, Novartis, and Teva as a consultant and/or speaker.